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METHODS: All subjects possessing an influenza diagno-
sis (ICD-9-CM  487) in PharMetrics’ Integrated Out-
comes Database between January 1, 1997 and June 30,
1998 were eligible for inclusion. Subjects with an influenza
diagnosis one-year prior to their index date and subjects
with less than 3 months of data available for analysis prior
to or following first diagnosis were excluded. Comorbidi-
ties, influenza vaccinations, antiviral and antibiotic pre-
scriptions were also identified during the study period.
RESULTS: A total of 18,000 subjects met all inclusion
criteria. The mean age of all subjects was 29.1 years (Std
Dev  20.7). Inpatient costs accounted for over 35% of
the $12.8 million in total costs incurred during the study
period, even though only 3% (472) of the sample required
hospitalization for influenza. The mean cost of an influ-
enza related hospitalization was $9,667 (Std Dev 
20,940) per subject hospitalized. Antibiotics were pre-
scribed in approximately 28% of the subjects, however an-
tivirals were prescribed to only (7%) of the subjects.
CONCLUSIONS: Although hospitalization for influenza
was rare (3%), the costs associated with this outcome
were significant. Prevention of hospitalizations related to
influenza could result in significant cost savings for man-
aged care organizations.
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OBJECTIVE: To assess the cost-effectiveness of pharma-
cotherapy for partners in a screening program for asymp-
tomatic infection with Chlamydia trachomatis (CT) in
women.
METHODS: A decision-analysis model was constructed
for the health outcomes of a CT screening program, such as
averted cases of pelvic inflammatory disease and infertility
(major outcomes). Prevalence estimates of CT-infection
and information on partner referral were derived from pi-
lot studies in Amsterdam (the Netherlands). Reinfection
due to failed partner referral or non-compliance with part-
ner pharmacotherapy was included in the model. Cost-
effectiveness from a societal perspective was estimated for a
screening program in General Practices in Amsterdam, di-
rected at women aged 15–29. For diagnosis of asymptom-
atic CT infection a Ligase Chain Reaction test on urine was
used, for pharmacotherapy of women and partners azithro-
mycin was used. By linking health outcomes with health-
care costs and productivity losses averted costs were esti-
mated. Cost-effectiveness was expressed as net costs per
major outcome averted and was calculated in the reference
case and in sensitivity analysis.
RESULTS: Partner pharmacotherapy induces reductions
of approximately 50% in net costs per major outcome
averted of the screening program. Within the broader
framework of the screening program partner pharmaco-
therapy is a cost-saving activity.
CONCLUSIONS: Inclusion of partner pharmacotherapy
provides significant improvements in overall cost-effective-
ness of the CT-screening program. Partner pharmacother-
apy lowers net costs per major outcome averted to realms
where implementation of the screening program for women
aged 15-29 should be considered. Implementation of the
program is currently discussed for the city of Amsterdam.
Given the cost-saving potentials, male partner pharmaco-
therapy should be pursued within broader framework of a
CT-screening program for women.
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The economic impact of administration of the extremely
expensive new amphotericin B (Amph B) preparations is
huge for Greek hospitals.
OBJECTIVE: The purpose of this study is to present the
cost of amphotericin B therapy and the cost-efficacy results,
after administration, of the three amphotericin prepara-
tions, available in the Greek market, in a third-grade univer-
sity hospital.
METHOD: 88 amphotericin prescriptions dispensed by
the Hospital Pharmacy were monitored over 2 months.
RESULTS:
1. The three preparations available in the hospital Phar-
macy are: A. Classic Amph B (Fungisone); B. Liposo-
mal Amph B (Am Bisome); C. Lipid-complexed Amph
B (ABLC). These are offered at the following prices (in
USD): A: 100 mg  1D, B: 100 mg  336D, C: 100
mg  106D
2. Duration of Amph B therapy: 18  3 days
3. Number of flacons per patient per day: Adults 5–12 fl;
Children: 5  1
4. Departments of major administration: Intensive Care
Units (Surgical-AIDS-Internal Medicine), Nephrology,
Pediatrics, Unit of Peritoneal Clearance
5. Cost of therapy: a. Costs per day, per patient A: 3D, B:
1680–3360D, C: 530–1060D. b. Costs of Total Ther-
apy per patient: A 30D, B 54.000  4.000 D. C.:
14.400  2.600 D
6. No clinical evidence has been provided yet, whether ad-
ministration of liposomal or lipid-complexed Amph B is
cost-effective and the optimum necessary dosage.
CONCLUSION: Extremely high costs for Amph B ther-
apy become a threat for Social Insurance, because hospi-
